Hairy-cell leukemia (HCL) and HCL-variant share some pathological features, but are distinct in morphology and immunophenotype. 1 Their differentiation is important for patient management and clinical outcome, with HCL-variant responding poorly to conventional HCL treatments and having a median survival of 9 years compared with over 20 years in HCL. 2 We have shown that HCL and HCL-variant exhibit different immunoglobulin heavy chain (IGH) gene repertoires and somatic hypermutation patterns, 3 consistent with their being two distinct diseases.
High-resolution genomic studies are limited in HCL and no such data are yet available for HCL-variant. Using highresolution single-nucleotide polymorphism (SNP) arrays, we examined DNA copy number aberrations (CNAs) and loss of heterozygosity (LOH) in 14 patients with typical HCL (male: female ratio ¼ 10:4; median age 50 years, range 37-79 years) and 15 with HCL-variant (male:female ratio ¼ 12:3; median age 73 years, range 42-93 years). The aim of the study was to compare the genomic imbalances in these two disorders to gain insight into the differences in their pathogenesis and clinical behavior.
The study was approved by the Royal Marsden Clinical Research and Research Ethics Committees. Cases were selected based on the availability of high-quality genomic DNA with high tumor-cell purity (485% tumor cells), acquired before treatment. Patients were diagnosed between 1982 and 2007 based on cell morphology, immunophenotyping and bone marrow and/or spleen histology according to the World Health Organization classification. 1 Details of their disease features have been previously documented. 3 Of the 14 patients with HCL, 3 had splenectomy and 10 had purine analogs (3 pentostatin and 7 cladribine); 1 patient did not require treatment. Of the 15 patients with HCL-variant, 9 had splenectomy and 5 had purine analogs (4 pentostatin and 1 cladribine); 1 patient did not require treatment. Survival data were available for 11/14 HCL (median follow-up 70 months; range: 4-227) and 12/15 HCL-variant (median follow-up 58 months; range: 1-189) cases.
CNAs (excluding the IGH and IGL heterogeneic loci) were identified in 11 (86%) HCL and 14 (93%) HCL-variant cases (Supplementary Tables 1 and 2 ). The mean number of lesions per patient in HCL was 3.4 (range ¼ 0-11) and in HCL-variant was 7.9 (range ¼ 0-27; P ¼ 0.1), with 3/15 HCL-variant cases exhibiting more than 20 aberrations. Genomic losses predominated over gains in both diseases (losses/gains: 28/19 in HCL; 81/37 in HCL-variant). Combination of copy number and LOH data revealed only two HCL-variant cases (HCLv-2 and HCLv-14) to have large regions of copy number-neutral LOH extending from the telomere, indicative of uniparental disomy (UPD). For one of these cases (HCLv-14) this involved the whole 6p region and for the other (HCLv-2) the majority of 2p (2p16.1-pter) and the whole of 11q (11q12.3-qter). Deletions for which LOH could not be detected (for example, case HCLv-1, Supplementary Tables 1 and 2 ) are likely to have resulted from the aberration being present in a minor sub-clone of the tumor population.
Certain chromosomes were more susceptible to gross aberrations (4200 kb). Chromosomes with overlapping CNAs in X2 HCL or HCL-variant cases are listed in Supplementary Tables 3  and 4 . Gains on chromosomes 5 (trisomy 5 and gains on 5q) and deletions on chromosomes 7q and 17p were found in X3 cases of HCL or HCL-variant, for which minimal gained regions (MGRs) and minimal deleted regions (MDRs) were determined ( Table 1 and Figure 1 ).
Gains on chromosome 5 have been reported to be the most frequent aberrations in typical HCL 4 and to be frequent in splenic marginal zone lymphoma (SMZL). We identified a high incidence of such aberrations in HCL-variant (5/15, 33%), but not in HCL cases (1/15, 7%). Two HCL-variant cases (HCLv-9 and HCLv-11) had trisomy 5 and the other three had gains on 5q. A single HCL case (HCL-2) had gain of the whole 5q arm. An MGR of approximately 19 Mb at 5q34-q35.3 was present in 5/6 patients with chromosome 5 gains ( Figure 1a ). This region encompasses over 200 known genes, including candidate tumor suppressor genes TLX3, FGF18, BNIP1, MSX2 and GFGR4.
Deletions on 7q affected equally both HCL (3/14 cases) and HCL-variant (3/15 cases). Two MDRs at 7q31.31-q31.33, approximately 4.1 and 0.6 Mb in size, defined by the two interstitial deletions present on 7q of an HCL-variant case (HCLv-9), were deleted in all six cases with 7q deletions (Figure 1b ). This aberration has been reported to be characteristic of HCL, 5 but we are the first to report its association with HCL-variant. Deletions on 7q are rare in other lymphoproliferative disorders, with the exception of SMZL, a disease that shares some features with HCL and HCL-variant. 1, 2 In SMZL, 7q deletions have been associated with unmutated IGH variable region (IGHV) genes and may have prognostic significance. The two MDRs we identified on 7q overlap with the previously reported MDRs for HCL and SMZL at 7q31.33-q33 (ref. 5 ) and contain a total of 33 known genes, including ING3, a tumor suppressor gene associated with head and neck cancers. The occurrence of 7q deletions in these three disorders suggests that deregulation of key tumor suppressor genes that reside within this region may be linked to their disease pathogenesis.
Partial or complete deletions of 17p, including TP53, occurred in 5/15 HCL-variant cases, but were absent in HCL (P ¼ 0.04) (Figure 1c) . HCL-variant cases with these deletions had significantly more genomic lesions (mean ¼ 18.8; range 6-27) than cases without (mean ¼ 2.4; range 0-5; P ¼ 0.02). Sequencing analysis identified TP53 mutations in the nondeleted allele in 3/5 17p-deleted HCL-variant cases, consisting of one missense mutation (HCLv-2: exon 5, 524G4A, R175H) and two splice-site mutations (HCLv-9: 7577598A4T, HCLv-12: 7576852G4T and 7576853T4C). This suggests loss of p53 function as the main target of this deletion. No mutations were detected in 7 HCL-variant and 10 HCL cases without 17p deletions. Two of the HCL-variant cases (HCLv-7 and HCL-v12) with complete loss of 17p had corresponding 17q trisomies extending from the centromere (Figure 1c) , indicative of isochromosome 17q formations. Such formations constitute a possible mechanism by which TP53 may be lost in HCL-variant cases, as in some cases of chronic lymphocytic leukemia (CLL) and SMZL.
In HCL-variant cases there was a significant association between 17p (TP53) deletion and shorter overall survival (P ¼ 0.015), with all 4 cases with 17p deletion and available survival data having died (100%) compared with 2/8 cases (25%) without deletion ( Table 2) . CLL patients with TP53 dysfunction are refractory to chemotherapy that targets the DNA damage cellular responses, and have a shorter progression-free and overall survival. Data on TP53 deletions are limited in HCLvariant and controversial in HCL. 6, 7 Recently it has been reported that two HCL cases refractory to 2-CDA treatment had mutated TP53. 8 Although we do not have such a clinical subgroup in our HCL series, our finding that TP53 deletion/ mutation is associated with poor outcome in HCL-variant is in agreement with this explanation of chemotherapy resistance and suggests that this aberration is a prognostic indicator for this disease. Furthermore, we have also found deletions on 17p to be associated with greater genomic instability in HCL-variant. Genomic complexity has been associated with 17p deletions and TP53 mutations in CLL and suggested to have prognostic impact.
All 3 of the HCL-variant cases with 7q deletions and 3/5 with chromosome 5 gains also had deletion on 17p. Association of these aberrations with 17p deletion in HCL-variant suggests that they may result from the TP53-related genomic instability. Furthermore, it should be noted that the minimal regions identified for the 7q deletions and chromosome 5 gains were defined by a small number of cases, and the majority of the aberrations extended over large regions. Analysis of additional cases may reveal that the critical regions of loss and gain reside elsewhere, and/or that they differ between HCL and HCLvariant, and perhaps also SMZL.
When the IGHV mutation status of the cases was considered, 2/3 (66%) of the HCL-variant cases with unmutated IGHV genes also had 17p deletion, compared with only 3/11 (27%) cases with mutated IGHV genes ( Table 2) ; this association was not statistically significant, possibly owing to the low number of cases.
In addition to gross CNAs, micro-deletions and micro-gains (o200 kb) were identified in both disorders (Supplementary  Tables 1 and 2 ). However, those that occurred in more than three cases were found to overlap with regions of known copy number variation according to the Database of Genomic Variants (http://projects.tcag.ca/variation/).
Homozygous deletions resulting in loss of function of key tumor suppressor genes may represent key events in tumor pathogenesis. The SNP arrays detected very few regions of homozygous loss for both HCL and HCL-variant (Supplementary  Tables 1 and 2 ). Such deletions were identified at 5q15 (HCL-10), 6p12 (HCLv-7 and HCLv-15) and 14q32.32 (HCLv-7), all of which spanned less than 100 kb. No known gene sequences reside within the 5q15-and 6p12-deleted regions. The 94.1-kb 14q32.32 deletion was found to harbor a single gene sequence, TRAF3, and was flanked either side by hemizygous deletion, covering a total of approximately 1.2 Mb (Figure 2 ). TRAF3, a tumor suppressor gene, encodes the tumor necrosis factorreceptor-associated factor 3, a negative regulator of the NF-kB pathway. Biallelic loss of TRAF3 has been associated with the pathogenesis of multiple myeloma (MM) and other B-cell malignancies through enhanced NF-kB activity. Homozygous deletion of TRAF3 in HCL-variant indicates that aberrant NF-kB signaling might have a role in the pathogenesis of this disorder. Gene expression profiling in additional cases of HCL-variant may reveal the deregulation of other key components of the NF-kB pathway. This is the first study to compare the genomes of HCL and HCL-variant at high resolution, allowing the identification of novel genetic lesions in both disorders and further defining known recurrent cytogenetic aberrations in HCL. Our data suggest that loss of TP53 may contribute to the greater genomic instability and to the aggressiveness and chemo-refractoriness of HCL-variant. Aside from the HCL-variants with 17p/TP53 deletion, the genomes of the remaining cases and those of HCL were relatively stable in contrast to other B-cell neoplasms such as CLL and MM. The dysfunction of other tumor suppressor and oncogenes, contained within the other imbalanced loci identified here, may have led to the drug resistance of the remaining HCL-variant cases. However, no single marker capable of distinguishing these two disorders was identified using this methodology. Integration of these mapping data with expression profiling data will further contribute to the identification of critical deregulated genes within these lesions.
